Donate

Cardiovascular Disease And Its Relationship With Androgen Deprivation (ADT)

Clinicians believe that there is an association between the risk of cardiovascular disease (CVD) and the duration and type of androgen-deprivation therapy (ADT) in men with prostate cancer. Researchers took data from 2006 to 2012 on filled drug prescriptions from the Swedish national health care registers. A cohort of 41,362 men with prostate cancer who were on ADT [...]

Long-Term Results Confirm Value of Adding Radio Therapy to ADT for Prostate Cancer Survival

There were many very interesting and very important items presented at the recent ASCO GU conference. Over the course of the next week or two I will be systematically reviewing many of these finds that have a direct impact on men with advanced prostate cancer. Today’s review is about how to create better results for [...]

Parenteral Estrogen May Reduce Hormone Agonist Toxicity in Advanced Prostate Cancer

First, I must apologize for having ignored the blog over the last two weeks. I have been intensely focused on the launch of a new project that we at Malecare have been developing. It has managed to take up every available second of my time. At this moment, I am not able to describe much [...]

From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

Changing ADT in the Treatment of Prostate Cancer – Are We Using It Correctly?

Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]

How to Manage the Side Effects of Hormone Therapy (ADT) in the Treatment of Prostate Cancer

David P. Wood, Jr., MD gave a presentation at the 9th International Prostate Forum (IPF) on October 8 - 10, 2009 in Izmir, Turkey on the Management the side effects of hormone therapy (ADT) when used to treat of prostate cancer. Dr. Wood indicated that the three major side effects of ADT in the treatment [...]

Hormone Therapy For Prostate Cancer Does Not Appear To Increase Cardiac Deaths

I have always assumed that treating my prostate cancer with a hormone blockade increases my risk of having a cardiovascular problem that increases my chance of death. Taking any drug is always a trade off, one benefit against the potential harms. It is a perfect risk-reward situation. However, there is some new research that makes [...]

Acupuncture Just As Effective Without Needle Puncture

When I was on a hormone block I suffered from many side effects, among them were the classical hot flashes. Some days I found that I would have to change shirts three to four times a day; Costco loved me because I eventually became their highest volume laundry detergent purchaser. One of my doctors suggested [...]

A Priority FDA Review for Toremifene 80 mg for Bone Protection

GTx announced in a company media release that it has requested that the FDA consider its new drug application (NDA) for the use of toremifene 80 mg to prevent bone fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). GTx has asked for a priority review of its application stating that “there are [...]

The FDA has approved the First Hormone Blockading Drug for Advanced Prostate Cancer

FDA just approved th first gonsdotropin-releasing hormone (GnRH) drug for the treatment of Advanced Prostate Cancer. This newly approved gonadotropin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone. Ferring Pharmaceuticals, USA (FP) received approval from the U.S. Food and Drug Administration (FDA) for degarelix, (generic name) which is a new injectable gonadotropin-releasing hormone [...]

Go to Top